| 冷洁，于德洪，张迪，尹敏▲.安罗替尼治疗晚期非小细胞肺癌的疗效及安全性分析[J].中国医药科学,2023,(20):150-153 基金项目: |
| 安罗替尼治疗晚期非小细胞肺癌的疗效及安全性分析 |
| Analysis on therapeutic efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer |
| |
| DOI： |
| 中文关键词: 安罗替尼；安全性；晚期非小细胞肺癌；有效性；不良反应发生率 |
| 英文关键词:Anlotinib; Safety; Advanced non-small cell lung cancer; Validity; Incidence of adverse reactions |
| 作者 | 单位 | | 冷洁，于德洪，张迪，尹敏▲ | 徐州医科大学附属邳州人民医院肿瘤科，江苏邳州 221300 |
|
| 摘要点击次数: 28 |
| 全文下载次数: 23 |
| 中文摘要: |
| [摘要]目的 探究安罗替尼对晚期非小细胞肺癌患者的治疗效果、生活质量的影响及耐受性的分析。方法 选取2020年1月至2023年1月徐州医科大学附属邳州人民医院收治的80例晚期非小细胞肺癌患者为研究对象，采用随机数表法分为对照组和观察组，每组各40例。对照组给予基础治疗，观察组给予安罗替尼治疗，比较两组患者的治疗效果。结果 观察组治疗效果高于对照组，差异有统计学意义（P < 0.05）。干预前，两组患者生活质量评分和Karnofsky评分比较，差异无统计学意义（P > 0.05）；干预后，观察组患者生活质量评分、Karnofsky评分高于对照组，差异有统计学意义（P < 0.05）。观察组不良反应总发生率低于对照组，差异有统计学意义（P < 0.05）。结论 晚期非小细胞肺癌患者采取安罗替尼治疗，疗效确切，临床症状显著改善，生活质量明显提高，治疗效果较好，患者副反应轻，耐受性良好，具有重要临床价值。 |
| 英文摘要: |
| [Abstract] Objective To investigate the therapeutic efficacy, impact on quality of life (QoL), and tolerance analysis of anlotinib in patients with advanced non-small cell lung cancer. Methods A total of 80 patients with advanced non-small cell lung cancer admitted to and treated in the Xuzhou Medical University Affiliated Pizhou People’s Hospital from January 2020 to January 2023 were selected as the research object, and they were divided into the control group (n=40) and the observation group (n=40) according to the random number table method. The control group was given the basic treatment, while the observation group was given the treatment of anlotinib, and the therapeutic efficacies of the two groups of patients were compared. Results Compared with the control group, the therapeutic efficacy of the observation group was higher, with statistically significant difference (P < 0.05). Before the intervention, there was not statistically significant difference in the QoL scores and Karnofsky score between the two groups (P > 0.05). After the intervention, the patients in the observation group had higher QoL scores and Karnofsky scores than that of the control group, with statistically significant differences (P < 0.05). And the incidence of adverse reactions was lower than that of the control group, with statistically significant difference (P < 0.05). Conclusion Patients with advanced non-small cell lung cancer are treated with anlotinib, which has definite therapeutic efficacy, obvious improvement of clinical symptoms, remarkable improvement of QoL, better therapeutic efficacy, mild side effects and good tolerance, and has important clinical value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)